Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 259

1.

Crizotinib in MET deregulated or ROS1 rearranged pretreated non-small-cell lung cancer (METROS): a phase II, prospective, multicentre, two-arms trial.

Landi L, Chiari R, Tiseo M, D'Incà F, Dazzi C, Chella A, Delmonte A, Bonanno L, Giannarelli D, Cortinovis DL, De Marinis F, Borra G, Morabito A, Gridelli C, Galetta D, Barbieri F, Grossi F, Capelletto E, Minuti G, Mazzoni F, Verusio C, Bria E, Alì G, Bruno R, Proietti A, Fontanini G, Crinò L, Cappuzzo F.

Clin Cancer Res. 2019 Aug 15. pii: clincanres.0994.2019. doi: 10.1158/1078-0432.CCR-19-0994. [Epub ahead of print]

PMID:
31416808
2.

Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations.

Simbolo M, Barbi S, Fassan M, Mafficini A, Ali G, Vicentini C, Sperandio N, Corbo V, Rusev B, Mastracci L, Grillo F, Pilotto S, Pelosi G, Pelliccioni S, Lawlor RT, Tortora G, Fontanini G, Volante M, Scarpa A, Bria E.

J Thorac Oncol. 2019 Sep;14(9):1651-1661. doi: 10.1016/j.jtho.2019.05.003. Epub 2019 May 11.

3.

Distinct Angiogenic microRNA-mRNA Expression Profiles Among Subtypes of Lung Adenocarcinoma.

Boldrini L, Giordano M, Melfi F, Lucchi M, Fontanini G.

Pathol Oncol Res. 2019 May 2. doi: 10.1007/s12253-019-00664-7. [Epub ahead of print]

PMID:
31044389
4.

Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens.

Pisapia P, Malapelle U, Roma G, Saddar S, Zheng Q, Pepe F, Bruzzese D, Vigliar E, Bellevicine C, Luthra R, Nikiforov YE, Mayo-de-Las-Casas C, Molina-Vila MA, Rosell R, Bihl M, Savic S, Bubendorf L, de Biase D, Tallini G, Hwang DH, Sholl LM, Vander Borght S, Weynand B, Stieber D, Vielh P, Rappa A, Barberis M, Fassan M, Rugge M, De Andrea CE, Lozano MD, Lupi C, Fontanini G, Schmitt F, Dumur CI, Bisig B, Bongiovanni M, Merkelbach-Bruse S, Büttner R, Nikiforova MN, Roy-Chowdhuri S, Troncone G; Molecular Cytopathology Meeting Group.

Cancer Cytopathol. 2019 May;127(5):285-296. doi: 10.1002/cncy.22134. Epub 2019 Apr 25.

PMID:
31021538
5.

Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization.

Schirripa M, Biason P, Lonardi S, Pella N, Pino MS, Urbano F, Antoniotti C, Cremolini C, Corallo S, Pietrantonio F, Gelsomino F, Cascinu S, Orlandi A, Munari G, Malapelle U, Saggio S, Fontanini G, Rugge M, Mescoli C, Lazzi S, Reggiani Bonetti L, Lanza G, Dei Tos AP, De Maglio G, Martini M, Bergamo F, Zagonel V, Loupakis F, Fassan M.

Clin Cancer Res. 2019 Jul 1;25(13):3954-3961. doi: 10.1158/1078-0432.CCR-19-0311. Epub 2019 Apr 9.

PMID:
30967421
6.

Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamics.

Di Desidero T, Orlandi P, Fioravanti A, Alì G, Cremolini C, Loupakis F, Gentile D, Banchi M, Cucchiara F, Antoniotti C, Masi G, Fontanini G, Falcone A, Bocci G.

Biochem Pharmacol. 2019 Jun;164:94-105. doi: 10.1016/j.bcp.2019.04.001. Epub 2019 Apr 3.

PMID:
30953637
7.

Whole transcriptome targeted gene quantification provides new insights on pulmonary sarcomatoid carcinomas.

Alì G, Bruno R, Poma AM, Affinito O, Monticelli A, Piaggi P, Ricciardi S, Lucchi M, Melfi F, Chella A, Cocozza S, Fontanini G.

Sci Rep. 2019 Mar 5;9(1):3536. doi: 10.1038/s41598-019-40016-8.

8.

Overexpression of the cohesin-core subunit SMC1A contributes to colorectal cancer development.

Sarogni P, Palumbo O, Servadio A, Astigiano S, D'Alessio B, Gatti V, Cukrov D, Baldari S, Pallotta MM, Aretini P, Dell'Orletta F, Soddu S, Carella M, Toietta G, Barbieri O, Fontanini G, Musio A.

J Exp Clin Cancer Res. 2019 Mar 1;38(1):108. doi: 10.1186/s13046-019-1116-0.

9.

Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer.

Fornaro L, Vivaldi C, Parnofiello A, Ugolini C, Aprile G, De Maglio G, Pecora I, Iacono D, Crivelli F, Catanese S, Cardellino GG, Lencioni M, Vasile E, Salani F, Clerico M, Calvetti L, Falcone A, Fasola G, Fontanini G, Montagnani F.

Br J Cancer. 2019 Mar;120(5):522-526. doi: 10.1038/s41416-019-0399-4. Epub 2019 Feb 12.

PMID:
30745584
10.

Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial.

Masi G, Vivaldi C, Fornaro L, Lonardi S, Buccianti P, Sainato A, Marcucci L, Martignetti A, Luca Urso ED, Castagna M, Fontanini G, Bergamo F, Musettini G, Urbani L, Sensi E, Balestri R, Montrone S, Pasqualetti F, Cremolini C, Di Paolo A, Zagonel V, Falcone A.

Eur J Cancer. 2019 Mar;110:32-41. doi: 10.1016/j.ejca.2019.01.006. Epub 2019 Feb 7.

PMID:
30739838
11.

Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial.

Cremolini C, Marmorino F, Bergamo F, Aprile G, Salvatore L, Masi G, Dell'Aquila E, Antoniotti C, Murgioni S, Allegrini G, Borelli B, Gemma D, Casagrande M, Granetto C, Delfanti S, Di Donato S, Schirripa M, Sensi E, Tonini G, Lonardi S, Fontanini G, Boni L, Falcone A.

Eur J Cancer. 2019 Mar;109:175-182. doi: 10.1016/j.ejca.2018.12.028. Epub 2019 Feb 5.

PMID:
30735919
12.

In Reply.

Alì G, Bruno R, Fontanini G.

Arch Pathol Lab Med. 2018 Dec;142(12):1452. doi: 10.5858/arpa.2018-0357-LE. No abstract available.

PMID:
30500281
13.

Expression profiling and microRNA regulation of the LKB1 pathway in young and aged lung adenocarcinoma patients.

Boldrini L, Giordano M, Lucchi M, Melfi F, Fontanini G.

Biomed Rep. 2018 Sep;9(3):198-205. doi: 10.3892/br.2018.1122. Epub 2018 Jul 2.

14.

Predictive markers in lung cancer: a few hints for the practicing pathologist.

Barbareschi M, Barberis M, Buttitta F, Doglioni C, Fiorentino M, Fontanini G, Franco R, Marchetti A, Rossi G, Troncone G.

Pathologica. 2018 Mar;110(1):29-38. Review.

PMID:
30259911
15.

Hippo pathway affects survival of cancer patients: extensive analysis of TCGA data and review of literature.

Poma AM, Torregrossa L, Bruno R, Basolo F, Fontanini G.

Sci Rep. 2018 Jul 13;8(1):10623. doi: 10.1038/s41598-018-28928-3.

16.

Nodal upstaging evaluation in NSCLC patients treated by robotic lobectomy.

Zirafa C, Aprile V, Ricciardi S, Romano G, Davini F, Cavaliere I, Alì G, Fontanini G, Melfi F.

Surg Endosc. 2019 Jan;33(1):153-158. doi: 10.1007/s00464-018-6288-8. Epub 2018 Jun 25.

PMID:
29943062
17.

Primary Tumor Sidedness and Benefit from FOLFOXIRI plus Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer.

Cremolini C, Antoniotti C, Lonardi S, Bergamo F, Cortesi E, Tomasello G, Moretto R, Ronzoni M, Racca P, Loupakis F, Zaniboni A, Tonini G, Buonadonna A, Marmorino F, Allegrini G, Granetto C, Masi G, Zagonel V, Sensi E, Fontanini G, Boni L, Falcone A.

Ann Oncol. 2018 Apr 20. doi: 10.1093/annonc/mdy140. [Epub ahead of print]

PMID:
29897402
18.

Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO.

Cremolini C, Antoniotti C, Lonardi S, Bergamo F, Cortesi E, Tomasello G, Moretto R, Ronzoni M, Racca P, Loupakis F, Zaniboni A, Tonini G, Buonadonna A, Marmorino F, Allegrini G, Granetto C, Masi G, Zagonel V, Sensi E, Fontanini G, Boni L, Falcone A.

Ann Oncol. 2018 Apr 20. doi: 10.1093/annonc/mdy140. [Epub ahead of print]

PMID:
29873679
19.

N2 lung cancer is not all the same: an analysis of different prognostic groups.

Bertoglio P, Ricciardi S, Alì G, Aprile V, Korasidis S, Palmiero G, Fontanini G, Mussi A, Lucchi M.

Interact Cardiovasc Thorac Surg. 2018 Nov 1;27(5):720-726. doi: 10.1093/icvts/ivy171.

PMID:
29788107
20.

Differential microRNA expression profiles between young and old lung adenocarcinoma patients.

Giordano M, Boldrini L, Servadio A, Niccoli C, Melfi F, Lucchi M, Mussi A, Fontanini G.

Am J Transl Res. 2018 Mar 15;10(3):892-900. eCollection 2018.

21.

Screen-detected multiple primary lung cancers in the ITALUNG trial.

Mascalchi M, Comin CE, Bertelli E, Sali L, Maddau C, Zuccherelli S, Picozzi G, Carrozzi L, Grazzini M, Fontanini G, Voltolini L, Vella A, Castiglione F, Carozzi F, Paci E, Zompatori M, Lopes Pegna A, Falaschi F; ITALUNG Study Research Group.

J Thorac Dis. 2018 Feb;10(2):1058-1066. doi: 10.21037/jtd.2018.01.95.

22.

Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.

Cremolini C, Milione M, Marmorino F, Morano F, Zucchelli G, Mennitto A, Prisciandaro M, Lonardi S, Pellegrinelli A, Rossini D, Bergamo F, Aprile G, Urbani L, Morelli L, Schirripa M, Cardellino GG, Fassan M, Fontanini G, de Braud F, Mazzaferro V, Falcone A, Pietrantonio F.

Br J Cancer. 2018 Apr;118(7):955-965. doi: 10.1038/s41416-018-0015-z. Epub 2018 Mar 13.

23.

Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review.

Bruno R, Alì G, Fontanini G.

J Thorac Dis. 2018 Jan;10(Suppl 2):S342-S352. doi: 10.21037/jtd.2017.10.88. Review.

24.

Surgery for malignant pleural mesothelioma: an international guidelines review.

Ricciardi S, Cardillo G, Zirafa CC, Carleo F, Facciolo F, Fontanini G, Mutti L, Melfi F.

J Thorac Dis. 2018 Jan;10(Suppl 2):S285-S292. doi: 10.21037/jtd.2017.10.16. Review.

25.

The pathological and molecular diagnosis of malignant pleural mesothelioma: a literature review.

Alì G, Bruno R, Fontanini G.

J Thorac Dis. 2018 Jan;10(Suppl 2):S276-S284. doi: 10.21037/jtd.2017.10.125. Review.

26.

Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.

Cremolini C, Antoniotti C, Lonardi S, Aprile G, Bergamo F, Masi G, Grande R, Tonini G, Mescoli C, Cardellino GG, Coltelli L, Salvatore L, Corsi DC, Lupi C, Gemma D, Ronzoni M, Dell'Aquila E, Marmorino F, Di Fabio F, Mancini ML, Marcucci L, Fontanini G, Zagonel V, Boni L, Falcone A.

JAMA Oncol. 2018 Apr 1;4(4):529-536. doi: 10.1001/jamaoncol.2017.5314.

27.

Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm.

Pelosi G, Bianchi F, Dama E, Simbolo M, Mafficini A, Sonzogni A, Pilotto S, Harari S, Papotti M, Volante M, Fontanini G, Mastracci L, Albini A, Bria E, Calabrese F, Scarpa A.

Virchows Arch. 2018 Apr;472(4):567-577. doi: 10.1007/s00428-018-2307-3. Epub 2018 Feb 1.

28.

Analysis of Fusion Genes by NanoString System: A Role in Lung Cytology?

Alì G, Bruno R, Savino M, Giannini R, Pelliccioni S, Menghi M, Boldrini L, Proietti A, Chella A, Ribechini A, Fontanini G.

Arch Pathol Lab Med. 2018 Apr;142(4):480-489. doi: 10.5858/arpa.2017-0135-RA. Epub 2018 Jan 26. Review.

PMID:
29372843
29.

EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas.

Petrini I, Lencioni M, Vasile E, Fornaro L, Belluomini L, Pasquini G, Ginocchi L, Caparello C, Musettini G, Vivaldi C, Caponi S, Ricci S, Proietti A, Fontanini G, Naccarato AG, Nardini V, Santi S, Falcone A.

Cancer Biomark. 2018 Feb 14;21(3):731-741. doi: 10.3233/CBM-170865.

PMID:
29278885
30.

miR-19a and miR-20a and Tissue Factor Expression in Activated Human Peripheral Blood Mononuclear Cells.

Balia C, Giordano M, Scalise V, Neri T, Fontanini G, Basolo F, Celi A, Pedrinelli R.

Thrombosis. 2017;2017:1076397. doi: 10.1155/2017/1076397. Epub 2017 Oct 30.

31.

Diaphragm and lung-preserving surgery with hyperthermic chemotherapy for malignant pleural mesothelioma: A 10-year experience.

Ambrogi MC, Bertoglio P, Aprile V, Chella A, Korasidis S, Fontanini G, Fanucchi O, Lucchi M, Mussi A.

J Thorac Cardiovasc Surg. 2018 Apr;155(4):1857-1866.e2. doi: 10.1016/j.jtcvs.2017.10.070. Epub 2017 Nov 1.

PMID:
29191688
32.

Role of microRNA-33a in regulating the expression of PD-1 in lung adenocarcinoma.

Boldrini L, Giordano M, Niccoli C, Melfi F, Lucchi M, Mussi A, Fontanini G.

Cancer Cell Int. 2017 Nov 17;17:105. doi: 10.1186/s12935-017-0474-y. eCollection 2017.

33.

Squamous cell transformation and EGFR T790M mutation as acquired resistance mechanisms in a patient with lung adenocarcinoma treated with a tyrosine kinase inhibitor: A case report.

Bruno R, Proietti A, Alì G, Puppo G, Ribechini A, Chella A, Fontanini G.

Oncol Lett. 2017 Nov;14(5):5947-5951. doi: 10.3892/ol.2017.6913. Epub 2017 Sep 8.

34.

Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study.

Cremolini C, Morano F, Moretto R, Berenato R, Tamborini E, Perrone F, Rossini D, Gloghini A, Busico A, Zucchelli G, Baratelli C, Tamburini E, Tampellini M, Sensi E, Fucà G, Volpi C, Milione M, Di Maio M, Fontanini G, De Braud F, Falcone A, Pietrantonio F.

Ann Oncol. 2017 Dec 1;28(12):3009-3014. doi: 10.1093/annonc/mdx546.

PMID:
29045518
35.

Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer.

Di Desidero T, Antonelli A, Orlandi P, Ferrari SM, Fioravanti A, Alì G, Fontanini G, Basolo F, Francia G, Bocci G.

Cancer Lett. 2017 Dec 28;411:35-43. doi: 10.1016/j.canlet.2017.09.032. Epub 2017 Sep 28.

PMID:
28964784
36.

KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease.

Viola D, Giani C, Mazzeo S, Ugolini C, Ciampi R, Molinaro E, Agate L, Borrelli N, Chella A, Fontanini G, Basolo F, Elisei R.

J Clin Endocrinol Metab. 2017 Sep 1;102(9):3091-3096. doi: 10.1210/jc.2017-00304.

PMID:
28911147
37.

Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors.

Mauro CD, Pesapane A, Formisano L, Rosa R, D'Amato V, Ciciola P, Servetto A, Marciano R, Orsini RC, Monteleone F, Zambrano N, Fontanini G, Servadio A, Pignataro G, Grumetto L, Lavecchia A, Bruzzese D, Iaccarino A, Troncone G, Veneziani BM, Montuori N, Placido S, Bianco R.

Sci Rep. 2017 Aug 24;7(1):9388. doi: 10.1038/s41598-017-10062-1.

38.

Detection of Mycobacterium tuberculosis from paraffin-embedded tissues by GeneXpert MTB/RIF.

Rindi L, Alì G, Fabiani B, Fontanini G, Garzelli C.

Tuberculosis (Edinb). 2017 Sep;106:53-55. doi: 10.1016/j.tube.2017.06.005. Epub 2017 Jul 3.

PMID:
28802405
39.

Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens.

Malapelle U, Mayo-de-Las-Casas C, Molina-Vila MA, Rosell R, Savic S, Bihl M, Bubendorf L, Salto-Tellez M, de Biase D, Tallini G, Hwang DH, Sholl LM, Luthra R, Weynand B, Vander Borght S, Missiaglia E, Bongiovanni M, Stieber D, Vielh P, Schmitt F, Rappa A, Barberis M, Pepe F, Pisapia P, Serra N, Vigliar E, Bellevicine C, Fassan M, Rugge M, de Andrea CE, Lozano MD, Basolo F, Fontanini G, Nikiforov YE, Kamel-Reid S, da Cunha Santos G, Nikiforova MN, Roy-Chowdhuri S, Troncone G; Molecular Cytopathology Meeting Group.

Cancer Cytopathol. 2017 Aug;125(8):615-626. doi: 10.1002/cncy.21868. Epub 2017 May 5.

40.

Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines.

Melaiu O, Catalano C, De Santi C, Cipollini M, Figlioli G, Pellè L, Barone E, Evangelista M, Guazzelli A, Boldrini L, Sensi E, Bonotti A, Foddis R, Cristaudo A, Mutti L, Fontanini G, Gemignani F, Landi S.

Genes Cancer. 2017 Jan;8(1-2):438-452. doi: 10.18632/genesandcancer.129.

41.

Prognostic role of TPL2 in early‑stage non‑small cell lung cancer.

Boldrini L, Giordano M, Servadio A, Niccoli C, Bertoglio P, Lucchi M, Melfi F, Mussi A, Fontanini G.

Mol Med Rep. 2017 Jun;15(6):3451-3458. doi: 10.3892/mmr.2017.6430. Epub 2017 Apr 3.

42.

Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months.

Marconcini R, Galli L, Antonuzzo A, Bursi S, Roncella C, Fontanini G, Sensi E, Falcone A.

Exp Hematol Oncol. 2017 Mar 21;6:6. doi: 10.1186/s40164-017-0067-4. eCollection 2017.

43.

Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients.

Carbone C, Piro G, Simionato F, Ligorio F, Cremolini C, Loupakis F, Alì G, Rossini D, Merz V, Santoro R, Zecchetto C, Zanotto M, Di Nicolantonio F, Bardelli A, Fontanini G, Tortora G, Melisi D.

Clin Cancer Res. 2017 Aug 1;23(15):4312-4322. doi: 10.1158/1078-0432.CCR-16-3153. Epub 2017 Mar 15.

44.

Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.

Cremolini C, Casagrande M, Loupakis F, Aprile G, Bergamo F, Masi G, Moretto R R, Pietrantonio F, Marmorino F, Zucchelli G, Tomasello G, Tonini G, Allegrini G, Granetto C, Ferrari L, Urbani L, Cillo U, Pilati P, Sensi E, Pellegrinelli A, Milione M, Fontanini G, Falcone A.

Eur J Cancer. 2017 Mar;73:74-84. doi: 10.1016/j.ejca.2016.10.028. Epub 2016 Dec 13.

PMID:
27986363
45.

Small cell lung cancer transformation and the T790M mutation: A case report of two acquired mechanisms of TKI resistance detected in a tumor rebiopsy and plasma sample of EGFR-mutant lung adenocarcinoma.

Alì G, Bruno R, Giordano M, Prediletto I, Marconi L, Zupo S, Fedeli F, Ribechini A, Chella A, Fontanini G.

Oncol Lett. 2016 Nov;12(5):4009-4012. Epub 2016 Sep 26.

46.

Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.

Simbolo M, Mafficini A, Sikora KO, Fassan M, Barbi S, Corbo V, Mastracci L, Rusev B, Grillo F, Vicentini C, Ferrara R, Pilotto S, Davini F, Pelosi G, Lawlor RT, Chilosi M, Tortora G, Bria E, Fontanini G, Volante M, Scarpa A.

J Pathol. 2017 Mar;241(4):488-500. doi: 10.1002/path.4853. Epub 2016 Dec 29.

47.

Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.

Bruno R, Alì G, Giannini R, Proietti A, Lucchi M, Chella A, Melfi F, Mussi A, Fontanini G.

Oncotarget. 2017 Jan 10;8(2):2758-2770. doi: 10.18632/oncotarget.13174.

48.

Aberrant expression of anaplastic lymphoma kinase in lung adenocarcinoma: Analysis of circulating free tumor RNA using one-step reverse transcription-polymerase chain reaction.

Bruno R, Giordano M, Giannini R, Alì G, Puppo G, Ribechini A, Chella A, Fontanini G.

Mol Med Rep. 2016 Sep;14(3):2238-42. doi: 10.3892/mmr.2016.5479. Epub 2016 Jul 7.

PMID:
27430882
49.

Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer.

Moretto R, Cremolini C, Rossini D, Pietrantonio F, Battaglin F, Mennitto A, Bergamo F, Loupakis F, Marmorino F, Berenato R, Marsico VA, Caporale M, Antoniotti C, Masi G, Salvatore L, Borelli B, Fontanini G, Lonardi S, De Braud F, Falcone A.

Oncologist. 2016 Aug;21(8):988-94. doi: 10.1634/theoncologist.2016-0084. Epub 2016 Jul 5.

50.

EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center.

Giannini R, Lupi C, Sensi E, Alì G, Proietti A, Boldrini L, Servadio A, Giordano M, Macerola E, Bruno R, Borrelli N, Chella A, Melfi F, Lucchi M, Ribechini A, Vasile E, Cappuzzo F, Mussi A, Fontanini G.

Oncol Rep. 2016 Aug;36(2):1166-72. doi: 10.3892/or.2016.4874. Epub 2016 Jun 14.

PMID:
27373829

Supplemental Content

Loading ...
Support Center